Clinical Question: What is the evidence for erosive lichen planus affecting the vulva being a premalignant condition?
However, ELPV is underresearched and evidence from larger-scale studies is lacking. This critically appraised topic 6 aims to evaluate the evidence to determine whether ELPV is associated with an increased risk of vulval SCC.
Literature Search
We searched the MEDLINE, EMBASE, and Cochrane Library databases on December 7, 2011 . The MEDLINE search strategy is illustrated in the Figure. No restrictions were imposed regarding the publication date, although articles were restricted to those in the English language. Overlap diagnoses of lichen sclerosus and lichen planus were excluded. Because case reports are subject to reporting bias and had the potential to skew our overall conclusion toward a positive association, we restricted our search to case series involving 5 or more consecutive patients with ELPV seen in a specialist clinic. The search strategy retrieved 142 articles. Of this number, 42 articles were selected for detailed review.
We identified 4 case series 7-10 that described the longterm follow-up of a total of 366 patients with ELPV. In addition, 2 case series 11, 12 of patients with anogenital carcinoma were found in which the authors investigated the underlying etiology of the malignancy. Five case reports 3,4,13-15 that described SCC occurring in association with ELPV (in a total of 6 patients) were also found; however, these were excluded.
Appraisal of the Evidence
Combining findings from the 4 case series, vulval SCC occurred in 5 of 366 patients. The overall duration of ELPV was reported for only 1 of these incident cases (3 years). 9 Mean follow-up time was documented by only 2 studies (60 9 and 72 8 months). Three studies were retrospective and 1 was prospective. These are summarized in the Table. Santegoets et al 7 performed a retrospective clinical study using medical records from 95 patients who pre- sented to a single vulval outpatient clinic in the Netherlands. Vulval SCC developed during follow-up in 2 patients. No further information was provided on duration of disease, age, response to treatment, or outcome following surgery for SCC.
Kennedy et al 9 reported a retrospective series of 113 patients who had presented to a specialty clinic with a new diagnosis of ELPV. Their primary aim was to assess the occurrence of cancer (of any type) in the patient cohort. Average follow-up for the entire cohort was stated as 5 years, although it is unclear whether this is the mean value and the range was not given. One patient developed vulval SCC 3 years after her diagnosis of ELPV. However, this was a relatively young patient (aged 40 years) who had received chemoradiotherapy 1 year earlier for likely human papillomavirus (HPV)-related cervical cancer. She also was relatively immunosuppressed secondary to medical comorbidities (Table) . In this series, a different patient developed oral SCC and another developed esophageal SCC. These patients had an underlying diagnosis of oral erosive lichen planus. Other seemingly unrelated malignant tumors also occurred within this cohort (Table) .
Kirtschig et al 10 retrospectively assessed the medical records of 44 patients. The mean follow-up was not stated. One patient developed vulval SCC 18 months after her first vulval symptoms. There was no comment about age of onset, severity, response to treatment of ELPV, comorbidities, or outcome following SCC treatment for this patient.
The only prospective cohort study identified was by Cooper and Wojnarowska, 8 who followed up 114 patients for a meanof72months.Vulvalintraepithelialneoplasiapreceded the development of vulval SCC in 1 patient. Squamous cell carcinomaoccurredinanother2patients,butthesiteaffected was the perianal location in 1 and the oral location in 1. It was implied, although this was not explicitly stated, that both of these sites were affected by erosive lichen planus before the development of malignancy. Vulval intraepithelial neoplasia occurred in another 6 patients. There was no comment on HPV status, comorbidities, the duration or severity of disease, or the response to treatment in the affected individuals. The prevalence of SCC development (any site) for this cohort was calculated at 3% during 72 months.
Of the 2 series that reviewed cases of anogenital carcinoma and investigated the underlying etiology, ELPV was implicated histologically in 6 of 84 occurrences of SCC. One study 11 identified 61 cases of vulval SCC from the histology department of a tertiary referral center and examined the adjacent epithelia for associated skin conditions. Eleven samples were excluded because adjacent epithelium was not present in the specimens. Epithelial disease was present in 40 of the 50 remaining specimens, 3 of which showed lichen planus. The sec- ond study 12 retrospectively analyzed the presence of coexisting skin disease in 21 women with vulval SCC. Clinical features of ELPV were present in 3 and histologic features were present in 4 of these patients. In these 2 studies, the vulval condition most commonly associated with SCC was, as expected, lichen sclerosus.
Limitations of the Critically Appraised Topic
The true incidence of ELPV is difficult to assess because patients present to a number of different specialists for treatment. Furthermore, unless an examining physician specifically asks, vulval disease may go undiagnosed in a patient whopresentswithlichenplanuselsewhere.Fewstudieshave been performed to characterize the natural history of ELPV and, to our knowledge, no randomized controlled trials to provide evidence for treatment have been published. 17 Only one of the studies that we identified had explicitly set out to determine the occurrence of cancer in patients with ELPV. 9 The remainder aimed to study clinical and histopathologic features and the response to treatment of the disease; assessing the development of malignant tumors was not their primary aim. Furthermore, only 1 study had been performed prospectively. 8 This could explain why certain information that would usually be included when reporting the development of malignant tumors in a cohort study (eg, follow-up period) was not available and we were therefore unable to calculate prevalence rates.
Although a description of how the clinical diagnosis was made was present in 2 articles, 7,9 it was not in the others. Specimens for histologic examination were not collected from all patients, and therefore we cannot be certain that all patients who developed SCC had a definite initial diagnosis of ELPV (although it is likely because all investigators were experts in their field).
Finally, except for the 1 patient reported by Kennedy et al, 9 there were no data offered regarding the possibility of latent infection with HPV in the patients who developed SCC. Because HPV is an important etiological factor in the development of anogenital intraepithelial neoplasia (and subsequent frank malignant tumor), it would be useful to gather data about HPV status in patients with ELPV in future prospective studies.
Clinical Bottom Line
The incidence of vulval carcinoma varies from less than 1 in 100 000 women in developing countries to more than 1.5 in 100 000 women in North America, South America, and Europe. 18 Insufficient data are present from the identified case series to calculate the incidence and prevalence of SCC within the population with ELPV. There is clear evidence that certain vulval inflammatory disorders, such as lichen sclerosus, 19 predispose to the development of malignancy. Although there is a suggestion of an increased prevalence of vulval SCC in patients with ELPV, the only way to clarify this is for long-term follow-up data of the disease and its complications to be recorded in a multicenter registry.
What Happened to Our Patient?
Following a reducing regimen of topical clobetasol propionate, 0.05%, our patient currently has adequate control of her disease with improved symptoms and function. She will continue with follow-up on a 3-to 6-month basis depending on the level of disease control. She has been educated about the importance of self-examination between clinic appointments to monitor for the development of malignant tumors. Given our current understanding, her follow-up will be long term owing to the perceived increased risk of developing SCC of the vulva associated with the ELPV. 
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